Extended Data Fig. 6: Light-inducible selective killing of CD19+ solid tumours in vivo using LiCAR-expressing T cells.
From: Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety
a, CD8+ LiCAR T-cells selectively destroy CD19-expressing melanoma in response to NIR light illumination. Left, C57BL/6 J mice were intradermally inoculated with 2.5×105 B16-OVA-hCD19 cells in the left flank and 2.5×105 B16-OVA cells (CD19-negative tumour as control) in the right flank. Two representative mice with opened tumour areas are shown after treatment with LiCAR T-cells + UCNPs and exposure to NIR pulses for 9 days. Right, isolated B16-OVA/UCNPs and B16-OVA-hCD19/UCNPs tumours at day 19. Green arrow, tumour cells. Blue arrow, UCNPs injected to tumour sites. The tumour masses after UCNP removal were shown in Fig. 3g. b, LiCAR T-cells permit NIR light-inducible killing of B16-OVA-hCD19 melanoma in selected regions. Left, C57BL/6 J mice were intradermally inoculated at both flanks with 3×105 B16-OVA-hCD19 cells. After injection with the LiCAR T-cells + UCNP mixture, the left flank was exposed to NIR pulses for 8 days, while the right side was protected from NIR light using aluminum foil. Two representative mice with opened tumours are shown at day 18. Right, isolated B16-OVA-hCD19/UCNPs tumours with and without NIR at day 18. Green arrow, tumour cells. Blue arrow, UCNPs injected to tumour sites. The tumour masses after UCNP removal were shown in Fig. 3h.
